EMBC logo

EMBECTA CORP

EMBCNASDAQ
🏆 #3091 by market capEarnings Nov 23 · PreUS Equity
$6.56▲ $0.10 (+1.55%)
Market closed · at close
🔔
Track EMBC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▼ 2.2%
14d▲ 4.4%
30d▲ 16.0%
ytd▼ 44.8%
1y▼ 51.9%
🏦Market Cap
$372M
Small Cap
📈Revenue Growth (YoY)
-7.6%
Declining
📊Gross Margin
59.0%
Healthy
💵FCF Margin
20.1%
Strong
⚖️P/S Ratio
0.4x
Cheap
Otter Score
72
Strong

Trading Snapshot

Day Range
$6.45 – $6.68
52-Week Range
$2.77 – $14.91
Volume (shares)
37,928
Avg Volume (shares)
—
Shares Outstanding
56.7M
Next Earnings
2026-11-23

Fundamentals Snapshot

Annual Revenue
$1.08B
Last Q Revenue
$272M
P/E Ratio
4.2
P/S Ratio
0.4x
EPS (TTM)
$1.48
Dividend Yield
7.32%
Dilution (1yr)
+0.5%
EMBC logo

EMBECTA CORP

EMBC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1B▼ −3.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
62.9%▼ −3.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$329M▲ +89.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$182M▲ +816.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.9M▲ +0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$1.2B▲ +$175M YoY
StockOtter · stockotter.space

About EMBECTA CORP

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100

Analyst Ratings

ⓘ
Consensus
Sell
9 analysts
Strong Buy0
Buy0
Hold5
Sell2
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.